BIOMAT Database Logo BIOMAT Database Logo

Association of anti-Ro/SSA antibody with response to biologics in patients with rheumatoid arthritis. 2016

Shinya Hagiwara, and Hiroto Tsuboi, and Fumika Honda, and Hidenori Takahashi, and Izumi Kurata, and Ayako Ohyama, and Mizuki Yagishita, and Saori Abe, and Yuko Kurashima, and Syunta Kaneko, and Hoshimi Kawaguchi, and Hiroyuki Takahashi, and Hiroshi Ebe, and Masahiro Yokosawa, and Hiromitsu Asashima, and Tomoya Hirota, and Naoto Umeda, and Yuya Kondo, and Isao Matsumoto, and Takayuki Sumida
a Department of Internal Medicine, Faculty of Medicine , University of Tsukuba , Ibaraki , Japan.

OBJECTIVE To compare the effectiveness of three different biologics in anti-Ro/SSA antibody-positive and antibody-negative patients with rheumatoid arthritis (RA). METHODS The study subjects were 110 biologics naïve patients with RA who started treatment with biologics and examined for anti-Ro/SSA antibody between December 2003 and March 2014. For patients treated with intravenous infliximab (IFX), tocilizumab (TCZ), or abatacept (ABT), we compared the clinical characteristics and changes in composite disease activity index, such as DAS28, SDAI, and CDAI, for 12 months in anti-Ro/SSA antibody-positive and antibody-negative patients. RESULTS We examined 59 patients (nine were positive and 50 were negative for anti-Ro/SSA antibody) treated with IFX, 27 patients (5 positive and 22 negative) treated with TCZ, and 24 patients (13 positive and 11 negative) treated with ABT. For patients treated with IFX, parameters of disease activity did not change significantly from baseline in anti-Ro/SSA antibody-positive patients, whereas they improved in antibody-negative patients. On the other hand, treatment with TCZ and ABT significantly decreased disease activity, relative to baseline, in both anti-Ro/SSA antibody-positive and antibody-negative patients. Anti-Ro/SSA antibody-positive patients treated with IFX showed higher frequency of HACA and seroconversion of ANA, and lower serum TGF-β levels. CONCLUSIONS Positivity to anti-Ro/SSA in RA seems to confer resistance to IFX via production of HACA and ANA, and low serum TGF-β levels, but not to TCZ and ABT.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069285 Infliximab A chimeric monoclonal antibody to TNF-ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE. Inflectra,Infliximab-abda,Infliximab-dyyb,MAb cA2,Monoclonal Antibody cA2,Remicade,Renflexis,Antibody cA2, Monoclonal,Infliximab abda,Infliximab dyyb,cA2, Monoclonal Antibody
D000069594 Abatacept A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS. BMS 188667,BMS-188667,BMS-224818,BMS224818,Belatacept,CTLA-4-Ig,CTLA4-Fc,CTLA4-Ig,CTLA4-Ig Immunoconjugate,Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin,LEA29Y,Nulojix,Orencia,BMS 224818,BMS188667,CTLA4 Ig Immunoconjugate,Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin,Immunoconjugate, CTLA4-Ig
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000974 Antibodies, Antinuclear Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease. Anti-DNA Antibodies,Antibodies, Anti-DNA,Antinuclear Antibodies,Antinuclear Autoantibodies,Antinuclear Autoantibody,Antinuclear Factors,Antinuclear Antibody,Antinuclear Factor,Anti DNA Antibodies,Antibody, Antinuclear,Autoantibody, Antinuclear,Factor, Antinuclear
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

Shinya Hagiwara, and Hiroto Tsuboi, and Fumika Honda, and Hidenori Takahashi, and Izumi Kurata, and Ayako Ohyama, and Mizuki Yagishita, and Saori Abe, and Yuko Kurashima, and Syunta Kaneko, and Hoshimi Kawaguchi, and Hiroyuki Takahashi, and Hiroshi Ebe, and Masahiro Yokosawa, and Hiromitsu Asashima, and Tomoya Hirota, and Naoto Umeda, and Yuya Kondo, and Isao Matsumoto, and Takayuki Sumida
Clinical significance of anti-Ro(SSA) antibody in rheumatoid arthritis.
March 1988, The Journal of rheumatology,
Shinya Hagiwara, and Hiroto Tsuboi, and Fumika Honda, and Hidenori Takahashi, and Izumi Kurata, and Ayako Ohyama, and Mizuki Yagishita, and Saori Abe, and Yuko Kurashima, and Syunta Kaneko, and Hoshimi Kawaguchi, and Hiroyuki Takahashi, and Hiroshi Ebe, and Masahiro Yokosawa, and Hiromitsu Asashima, and Tomoya Hirota, and Naoto Umeda, and Yuya Kondo, and Isao Matsumoto, and Takayuki Sumida
Rheumatoid factors in Ro (SSA) positive and Ro (SSA) negative rheumatoid arthritis patients.
January 1986, Rheumatology international,
Shinya Hagiwara, and Hiroto Tsuboi, and Fumika Honda, and Hidenori Takahashi, and Izumi Kurata, and Ayako Ohyama, and Mizuki Yagishita, and Saori Abe, and Yuko Kurashima, and Syunta Kaneko, and Hoshimi Kawaguchi, and Hiroyuki Takahashi, and Hiroshi Ebe, and Masahiro Yokosawa, and Hiromitsu Asashima, and Tomoya Hirota, and Naoto Umeda, and Yuya Kondo, and Isao Matsumoto, and Takayuki Sumida
[Anti-TNFalpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies].
December 2005, Reumatismo,
Shinya Hagiwara, and Hiroto Tsuboi, and Fumika Honda, and Hidenori Takahashi, and Izumi Kurata, and Ayako Ohyama, and Mizuki Yagishita, and Saori Abe, and Yuko Kurashima, and Syunta Kaneko, and Hoshimi Kawaguchi, and Hiroyuki Takahashi, and Hiroshi Ebe, and Masahiro Yokosawa, and Hiromitsu Asashima, and Tomoya Hirota, and Naoto Umeda, and Yuya Kondo, and Isao Matsumoto, and Takayuki Sumida
Anti-Ro (SSA) antibodies in rheumatoid arthritis patients with gold-induced side effects.
January 1997, Rheumatology international,
Shinya Hagiwara, and Hiroto Tsuboi, and Fumika Honda, and Hidenori Takahashi, and Izumi Kurata, and Ayako Ohyama, and Mizuki Yagishita, and Saori Abe, and Yuko Kurashima, and Syunta Kaneko, and Hoshimi Kawaguchi, and Hiroyuki Takahashi, and Hiroshi Ebe, and Masahiro Yokosawa, and Hiromitsu Asashima, and Tomoya Hirota, and Naoto Umeda, and Yuya Kondo, and Isao Matsumoto, and Takayuki Sumida
Genetic studies of anti-Ro (SSA) antibodies in families with rheumatoid arthritis.
February 1992, The Journal of rheumatology,
Shinya Hagiwara, and Hiroto Tsuboi, and Fumika Honda, and Hidenori Takahashi, and Izumi Kurata, and Ayako Ohyama, and Mizuki Yagishita, and Saori Abe, and Yuko Kurashima, and Syunta Kaneko, and Hoshimi Kawaguchi, and Hiroyuki Takahashi, and Hiroshi Ebe, and Masahiro Yokosawa, and Hiromitsu Asashima, and Tomoya Hirota, and Naoto Umeda, and Yuya Kondo, and Isao Matsumoto, and Takayuki Sumida
Clinical implications of the presence of anti-Ro (SSA) antibodies in patients with rheumatoid arthritis.
August 1988, Journal of autoimmunity,
Shinya Hagiwara, and Hiroto Tsuboi, and Fumika Honda, and Hidenori Takahashi, and Izumi Kurata, and Ayako Ohyama, and Mizuki Yagishita, and Saori Abe, and Yuko Kurashima, and Syunta Kaneko, and Hoshimi Kawaguchi, and Hiroyuki Takahashi, and Hiroshi Ebe, and Masahiro Yokosawa, and Hiromitsu Asashima, and Tomoya Hirota, and Naoto Umeda, and Yuya Kondo, and Isao Matsumoto, and Takayuki Sumida
Multiple tendon ruptures in a patient affected by anti-SSA/Ro antibody positive rheumatoid arthritis.
November 1997, Clinical rheumatology,
Shinya Hagiwara, and Hiroto Tsuboi, and Fumika Honda, and Hidenori Takahashi, and Izumi Kurata, and Ayako Ohyama, and Mizuki Yagishita, and Saori Abe, and Yuko Kurashima, and Syunta Kaneko, and Hoshimi Kawaguchi, and Hiroyuki Takahashi, and Hiroshi Ebe, and Masahiro Yokosawa, and Hiromitsu Asashima, and Tomoya Hirota, and Naoto Umeda, and Yuya Kondo, and Isao Matsumoto, and Takayuki Sumida
Anti-Ro/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations.
January 2006, Clinical and experimental rheumatology,
Shinya Hagiwara, and Hiroto Tsuboi, and Fumika Honda, and Hidenori Takahashi, and Izumi Kurata, and Ayako Ohyama, and Mizuki Yagishita, and Saori Abe, and Yuko Kurashima, and Syunta Kaneko, and Hoshimi Kawaguchi, and Hiroyuki Takahashi, and Hiroshi Ebe, and Masahiro Yokosawa, and Hiromitsu Asashima, and Tomoya Hirota, and Naoto Umeda, and Yuya Kondo, and Isao Matsumoto, and Takayuki Sumida
Possible association of "shrinking lung" and anti-Ro/SSA antibody.
November 2000, Arthritis and rheumatism,
Shinya Hagiwara, and Hiroto Tsuboi, and Fumika Honda, and Hidenori Takahashi, and Izumi Kurata, and Ayako Ohyama, and Mizuki Yagishita, and Saori Abe, and Yuko Kurashima, and Syunta Kaneko, and Hoshimi Kawaguchi, and Hiroyuki Takahashi, and Hiroshi Ebe, and Masahiro Yokosawa, and Hiromitsu Asashima, and Tomoya Hirota, and Naoto Umeda, and Yuya Kondo, and Isao Matsumoto, and Takayuki Sumida
[TNF-alpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunologic effects].
January 2006, Reumatismo,
Copied contents to your clipboard!